摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate | 1085709-12-1

中文名称
——
中文别名
——
英文名称
methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate
英文别名
——
methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate化学式
CAS
1085709-12-1
化学式
C20H16N2O4
mdl
——
分子量
348.358
InChiKey
PSVXHJQADNRMGP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    84.4
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate1-羟基苯并三唑N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下, 以 四氢呋喃 为溶剂, 反应 50.5h, 生成 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxyl-Trp-Trp-Glu(OBzl)-OBzl
    参考文献:
    名称:
    一类新型β-咔啉衍生物的合成与生物学评价
    摘要:
    在这项研究中,设计并合成了几种新型的β-咔啉衍生物,即1-(4-羟基-3-甲氧基苯基)-β-咔啉-3-羧基-Trp-Trp-AA-OBzl化合物,作为潜在的抗癌剂。使用甲基噻唑四唑(MTT)分析评估了它们的体外细胞毒性活性。的体内新合成的β咔啉衍生物的抗肿瘤活性是在一个轴承S180小鼠模型确定,并且一些化合物表现出类似于阳性对照,多柔比星的肿瘤生长抑制。还研究了小牛胸腺(CT)DNA合成的β-咔啉衍生物的嵌入。
    DOI:
    10.1039/c4nj00262h
  • 作为产物:
    描述:
    香草醛 在 selenium(IV) oxide 、 氯化亚砜溶剂黄146 作用下, 反应 1.0h, 生成 methyl 1-(4-hydroxy-3-methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylate
    参考文献:
    名称:
    一类新型β-咔啉衍生物的合成与生物学评价
    摘要:
    在这项研究中,设计并合成了几种新型的β-咔啉衍生物,即1-(4-羟基-3-甲氧基苯基)-β-咔啉-3-羧基-Trp-Trp-AA-OBzl化合物,作为潜在的抗癌剂。使用甲基噻唑四唑(MTT)分析评估了它们的体外细胞毒性活性。的体内新合成的β咔啉衍生物的抗肿瘤活性是在一个轴承S180小鼠模型确定,并且一些化合物表现出类似于阳性对照,多柔比星的肿瘤生长抑制。还研究了小牛胸腺(CT)DNA合成的β-咔啉衍生物的嵌入。
    DOI:
    10.1039/c4nj00262h
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DU SYNDROME MÉTABOLIQUE
    申请人:SJT MOLECULAR RES S L
    公开号:WO2012130912A1
    公开(公告)日:2012-10-04
    Present invention refers to new compounds of formula I or II, its synthesis and its use in the treatment of metabolic syndrome, particularly for the treatment of type I or type II diabetes and/or metabolic syndrome or metabolic disease or metabolic disorders.
    本发明涉及公式I或II的新化合物,其合成以及在治疗代谢综合征中的应用,特别是用于治疗I型或II型糖尿病和/或代谢综合征或代谢疾病或代谢紊乱。
  • Discovery of novel phosphatidylcholine-specific phospholipase C drug-like inhibitors as potential anticancer agents
    作者:Chatchakorn Eurtivong、Lisa I. Pilkington、Michelle van Rensburg、Reuben M. White、Harpreet Kaur Brar、Shaun Rees、Emily K. Paulin、Chris Sun Xu、Nabangshu Sharma、Ivanhoe K.H. Leung、Euphemia Leung、David Barker、Jóhannes Reynisson
    DOI:10.1016/j.ejmech.2019.111919
    日期:2020.2
    Phosphatidylcholine-specific phospholipase C (PC-PLC) is a promising target for new anticancer treatment. Herein, we report our work in the discovery of novel drug-like PC-PLC inhibitors. Virtual screening led to the identification of promising hits from four different structural series that contain the molecular scaffold of benzenesulphonamides (10), pyrido[3,4-b]indoles (22), morpholinobenzoic acid (84) and benzamidobenzoic acid (80). 164 structural analogues were tested to investigate the chemical space around the hit series and to generate preliminary structurally activity relationships (SAR). Two of the pyrido[3,4-b]indoles (22_10 and 22_15) had comparable or better potency as D609, an established but non-drug-like PC-PLC inhibitor. Furthermore, three morpholinobenzoic acids (84, 84_4 and 84_5) had superior potency than D609. Therefore, this study paves the way towards the development of drug-like PL-PLC inhibitors as potential anticancer agents. (C) 2019 Elsevier Masson SAS. All rights reserved.
  • Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) β-carboline derivatives
    作者:Anelise S. Nazari Formagio、Lilian T. Düsman Tonin、Mary Ann Foglio、Christiana Madjarof、João Ernesto de Carvalho、Willian Ferreira da Costa、Flávia P. Cardoso、Maria Helena Sarragiotto
    DOI:10.1016/j.bmc.2008.10.008
    日期:2008.11
    Several novel 1-substituted-phenyl beta-carbolines bearing the 2-substituted-1,3,4-oxadiazol-5-yl and 5-substituted-1,2,4-triazol-3-yl groups at C-3 were synthesized and evaluated for their in vitro anticancer activity. The assay results pointed thirteen compounds with growth inhibition effect (GI(50) < 100 mu M) for all eight different types of human cancer cell lines tested. The b-carbolines 7a and 7h, bearing the 3-(2-metylthio-1,3,4-oxadiazol-5-yl) group, displayed high selectivity and potent anticancer activity against ovarian cell line with GI50 values lying in the nanomolar concentration range (GI(50) = 10 nM for both compounds). The 1-(N,N-dimethylaminophenyl)-3-(5-thioxo-1,2,4-triazol-3-yl) beta-carboline (8g) was the most active compound, showing particular effectiveness on lung (GI(50) = 0.06 mu M), ovarian and renal cell lines. The potent anticancer activity presented for synthesized compounds 7a, 7h, and 8g, together with their easiness of synthesis, makes these compounds promising anticancer agents. (C) 2008 Elsevier Ltd. All rights reserved.
  • Synthesis and anti-Mycobacterium tuberculosis activity of imide-β-carboline and carbomethoxy-β-carboline derivatives
    作者:Mariana Aparecida Lopes-Ortiz、Manuela Ribeiro Panice、Eduardo Borges de Melo、João Paulo Ataide Martins、Vanessa Pietrowski Baldin、Cláudia Terêncio Agostinho Pires、Katiany Rizzieri Caleffi-Ferracioli、Vera Lúcia Dias Siqueira、Regiane Bertin de Lima Scodro、Maria Helena Sarragiotto、Rosilene Fressatti Cardoso
    DOI:10.1016/j.ejmech.2019.111935
    日期:2020.2
    A series of methyl beta-carboline carboxylates (2a-g) and of imide-O-carboline derivatives containing the phthalimide (4a-g), maleimide (5b, g) and succinimide (6b, e, g) moiety were synthesized, and evaluated for their activity against Mycobacterium tuberculosis H(37)Rv. The most active beta-carboline derivatives against the reference strain were assayed for their cytotoxicity and the activity against resistant M. tuberculosis clinical isolates. Farther, structure-activity relationship (SAR) studies were carried out using the three and four-dimensional approaches for starting to understand the way of beta-carboline activity in M. tuberculosis. All 19 beta-carboline derivatives were assayed, firstly, by determining the minimum inhibitory concentration (MIC) using resazurin microtiter assay plate (REMA) in M. tuberculosis H 37 Rv. Then, five derivatives (2c, 4a, 4e, 4g, 6g), which showed MIC <= 125 mu g/mL, were assayed in nine resistant M. tuberculosis clinical isolates (five MDR, three isoniazid monoresistant and one isoniazid plus streptomycin resistant). The MIC values against the resistant clinical isolates ranged from 31.25 to >250 mu g/mL. All five derivatives were non-cytotoxic to the VERO cell line, determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, at the tested concentration (selectivity index ranged from <1.74 to 14.4). Our study demonstrated that (2c) and (6g) derivatives had better antiM. tuberculosis activity, especially against resistant clinical isolates, what makes them scaffold candidates for further investigations about their anti-tuberculosis activity. The SAR study conducted with the 19 beta-carboline derivatives showed the importance of steric effects for the synthesized beta-carbolines against M tuberculosis, and these models can be used for future proposition of new derivatives, increasing the chances of obtaining potentially anti-tuberculosis compounds. (C) 2019 Elsevier Masson SAS. All rights reserved.
查看更多